Pharmacogenetics in Europe: Barriers and Opportunities

Abstract

This paper reviews the current situation in the field of pharmacogenetics/pharmacogenomics (PGx) in Europe. High expectations surrounding the clinical application of PGx remain largely unmet, as only a limited number of such applications have actually reached the market and clinical practice. Thus, the potential impact of PGx-based diagnostics on healthcare and its socio-economic implications are still unclear. With the aim of shedding some light on these uncertainties, the Institute for Prospective Technological Studies (IPTS) of the European Commission’s Joint Research Centre (JRC) has conducted a review of the ‘state of the art’ and a further analysis on the use of pharmacogenetics diagnostics for preventing toxic drug reactions and improving drug efficacy in Europe. The paper presents highlights from the JRC-IPTS studies and discusses possibilities for improving translation of PGx research in Europe by comparing some experiences in the USA. We also illustrate the related barriers for the clinical uptake of PGx in Europe with specific case-studies. Most of the barriers identified extend beyond the European context. This reflects the global problems of scarcity of data demonstrating proven clinical validity or utility and favorable cost-effectiveness studies to support the clinical application of PGx diagnostic tests in the clinical setting. Another key barrier is the lack of incentives for the private sector to invest in the development and licensing of PGx diagnostic tests for improving the safety and efficacy of out-of-patent drugs. It therefore seems that one key aspect where policy can affect the clinical uptake of PGx is via sustaining large-scale industry-academia collaborations for developing and proving the utility of PGx diagnostics.

Combining the scenario technique with bibliometrics for technology foresight: The case of personalized medicine

“…This finding supports the assumption that PM is primarily geared toward markets in developed countries because the costs for the diagnostics procedures are still rather high even though they have decreased dramatically in the last years (Moch et al, 2012;Faulkner et al, 2012;Gurwitz et al, 2009).…”

Pharmacogenetics: Matching the Right Foundation at Personalized Medicine in the Right Genomic Era

“…(Spraggs et al, 2009;Gurwitz et al, 2009) Scientific community and International Society of Pharmacogenomics Education Forum have called for the enhanced implementation of pharmacogenomics and personalized medicine into core medical teaching curricula and practice, in order to fill in the gap between intensive research on validated pharmacogenetic testing and its appropriate, effective clinical integration and interpretation in routine individualized therapy. (Squassina et al, 2010) For instance, Pharmacogenomics Education Program (PharmGenEd™) is an educational platform for dissemination of evidence-based clinically relevant pharmacogenomics, fostering educational and scientific collaboration among educators, researchers and clinicians (http://pharmacogenomics.ucsd.edu).…”

Pharmakogenomik:HypeoderHope?

“…Grund dafür ist ihr propagiertes Konzept einer individualisierten oder personalisierten Medizin, bei der der Anspruch, jedem Patienten eine zielgerichtete und maßgeschneiderte Therapie zukommen zu lassen, im Mittelpunkt steht. Da die klinische Realität heute jedoch noch weit von diesem Ziel entfernt ist [13,28], besteht bei Klinikern die berechtigte Skepsis, ob und in welchem Umfang die Pharmakogenomik tatsächlich die in sie gesetzten Erwartungen erfüllen kann.…”